Navigation Links
Bovine Serum Albumin Peroxidase Stabilizer Solution from BioFX Laboratories, Inc.

ProductsBovine Serum Albumin Peroxidase Stabilizer Solution from BioFX Laboratories, Inc.
Company BioFX Laboratories, Inc.
Item Bovine Serum Albumin Peroxidase Stabilizer Solution
Price $244.00
Description Bovine Serum Albumin Peroxidase Stabilizer Solution, 1 L
Info BioFX Laboratories, Inc.BioFX Laboratories, Inc.
10715 Red Run Blvd., Suite 114
Owings Mills, MD 21117

Call BioFX Laboratories, Inc. to buy products (US and Canada only; other locations use numbers below)
USA Canada 1-410-504-6961
Customer Service: 410-902-0281
Fax Number: 410-902-0551
Web Site: http://www.biofx.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Bovine rhodopsin Neutralizing Peptide from ABR-Affinity BioReagents
2. Bovine IFN gamma ELISPOT Kit from Endogen
3. Bovine Phosphatase, Alkaline bovine intestinal mucosa, Unconjugated from Sigma-Aldrich
4. Sheep Anti-Bovine BETA-LACTOGLOBULIN A Polyclonal Antibody, Unconjugated from AbD Serotec
5. Mouse Anti-Bovine GTP BINDING PROTEIN Monoclonal Antibody, Unconjugated, Clone 1H6 from AbD Serotec
6. Bovine Phosphatase, Alkaline, Unconjugated from Sigma-Aldrich
7. Bovine Serum, Adult from Sigma-Aldrich
8. Bovine Serum, Sterile Filtered from Meridian Life Science, Inc.
9. Rabbit Anti-Bovine Xanthine Oxidase, Buttermilk Polyclonal Antibody, Horseradish Peroxidase Conjugated from Meridian Life Science, Inc.
10. Rabbit Anti-Bovine Xanthine Oxidase, Buttermilk Polyclonal Antibody, Unconjugated from Meridian Life Science, Inc.
11. Bovine Calf Blood Non-Sterile Alsevers from Pel-Freez Biologicals
Breaking Biology Technology:EUCODIS Bioscience Appoints Thomas Fischer as New CEO 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2